350 rub
Journal Technologies of Living Systems №8 for 2010 г.
Article in number:
S100A8 and A100A9 expression in psoriatic skin
Keywords: psoriasis S100A8 S100A9 gene expression PUVA-therapy
Authors:
S.A. Ilyina, A.D. Zolotarenko, A.L. Piruzyan, M.T. Minnibaev, S.A. Bruskin, V.V. Sobolev
Abstract:
We have performed quantitive analysis of S100A8 and S100A9 gene expression in psoriatic skin. Gene expression profiles of involved and uninvolved (visually healthy) psoriatic skin were evaluated before and after PUVA therapy of 4 patients with severe psoriasis and 4 patients with mild psoriasis. Patients with mild psoriasis have not gain any systemic or PUVA/UV therapy before the biopsy sampling, and patients with severe psoriasis have gain systemic therapy for some years. One month before the biopsy sampling none of the patients got any systemic or PUVA/UV therapy. We have shown an important up-regulation of S100A8 and S100A9 gene expression in involved psoriatic skin compared to visually uninvolved skin of the same patients. After PUVA therapy down-regulation of S100A8 and S100A9 expression is observed almost in all samples. During the experimental procedures we have discovered that S100 A8 and A100A9 expression at one patient, who gained not only PUVA therapy, but also a therapy with hormone-based drug «КЕNАLОG», was not down-regulated, but even slightly up-regulated. The change of S100A8 and S100A9 gene expression before and after the therapy have shown a clear tendency to the down-regulation of mRNA level after successful therapy, excluding one pa-tient, and this phenomenon is correlated to the positive dynamics of the patienthood. We suppose that a high expression level of S100A8 and S100A9 genes could be a criterion of psoriatic process, and transcriptional activity of S100A8 and S100A9 genes could be used as of a molecular indicator of therapy efficiency.
Pages: 45-51
References
  1. Boehncke W.H., Dressel D., Zollner T.M., KaufmannR.Pulling the trigger on psoriasis // Nature. 1996. V. 379(6568). P. 777.
  2. Ortonne J.P. Aetiology and pathogenesis of psoriasis // Br. J. Dermatol. 1996. V.135(Suppl 49). P. 1-5.
  3. Peters B., Weissman F., Gill M. Pathophysiology and treatment of psoriasis.// Am. J. Health Syst. Pharm. 2001. V. 57, №7. P.645-59.
  4. Nickoloff B., Nestle F. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities.// J. Clin. Invest. 2004. V. 113. № 12. P.1664-75.
  5. Schon M, Boehncke W. Psoriasis // N. Engl. J. Med. 2005. V.352.№ 18. P.1899-912.
  6. Пирузян Э.С., Никольская Т.А., Абдеев Р.М. и др. Компоненты транскрипционного фактора AP-1 как гены-кандидаты, участвующие в развитии псориатического процесса // Молекулярная биология. 2007. Т. 41. С. 1069-1080.
  7. Пирузян Э.С., Ишкин А.А., Никольская Т.А.и др. Сравнительный анализ молекулярно-генетических процессов при патогенезе псориаза и болезни Крона // Молекулярная биология. 2009. Т. 43. № 1. С. 175-179.
  8. Lee W., Mitchell P. Purified transcription factor AP-1 interacts with TPA inducible enhancer elements // Cell. 1987. V. 49. № 6. P. 741-52.
  9. Chen L., Glover N. Structure of the DNA-binding domains from NFAT, Fos and Jun bound specifically to DNA // Nature. 1998. V. 392. № 6671. P. 42-8.
  10. Соболев В.В., Золотаренко А.Д., Соболева А.Г. и др. Экспрессия гена FOSL1при псориазе и атеросклерозе // Генетика. 2010. Т. 46. № 1. С. 104-110.
  11. Пирузян Э.С., Корсунская И.М.,Соболев В.В. и др. Разработка новых подходов к оценке на молекулярном уровне эффективности лечения псориаза // Технологии живых систем. 2009. Т. 6. № 7. С. 16-23.
  12. Zenz R., Eferl R., Kenner L. et al.Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins // Nature. 2005. V. 437. P. 369-375.
  13. Vandal K., Rouleau P., Boivin A. et al. Blockade of S100A8 and S100A9 suppresses neutrophil migration in response to lipopolysaccharide // J. Immunol. 2003. V.171. P. 2602-2609.
  14. Bantel H., Schmitz M., Raible A. et al. Critical role of NF-kappaB and stress-activated protein kinases in steroid unresponsiveness //FASEB J. 2002. V. 16. № 13. P. 1832-4.
  15. Gonsky R., Deem R., Hughes C.et al.Activation of the CD2 pathway in lamina propria T cells up-regulates functionally active AP-1 binding to the IL-2 promoter, resulting in messenger RNA transcription and IL-2 secretion //J. Immunol. 1998. V. 160. № 10. P. 4914-22.
  16. Брускин С.А., Абдеев Р.М., Мошковский С.А. и др. Протеомные исследования псориаза как подход к идентификации потенциальных мишеней фармакотерапии // Клиническая дерматология и венерология. 2009. №1. С. 28-31.
  17. Пирузян Э.С., Соболев В.В., Абдеев Р.М. и др. Изучение молекулярных механизмов патогенеза иммуно-опосредованных воспалительных заболеваний на примере псориаза // ActaNaturae. 2009. №3. С.139-150.
  18. Hardas B.D., Zhao X., Zhang J. et al.Assignment of psoriasin to human chromosomal band 1q21: coordinate overexpression of clustered genes in psoriasis // J. Invest. Dermatol. 1996. V. 106. P. 753-758.
  19. Semprini S., Capon F., Tacconelli A. et al.  Evidence for differential S100 gene over-expression in psoriatic patients from genetically heterogeneous pedigrees // Hum. Genet.2002. V. 111. P. 310-313.
  20. Piruzian E, Bruskin S, Ishkin A. et al. Integrated network analysis of transcriptomic and proteomic data in psoriasis // BMC Syst Biol. 2010. V. 4. P. 41.
  21. Broome A.M, Ryan D, Eckert R.L. S100 protein subcellular localization during epidermal differentiation and psoriasis // J. Histochem. Cytochem. 2003. V. 51 P. 675-85.
  22. MadsenP, RasmussenHH, LeffersHet al.Molecular cloning, occurrence, and expression of a novel partially secreted protein 'psoriasin' that is highly up-regulated in psoriatic skin // J. Invest. Dermatol.1991. V.97. P.701-12
  23. BroomeA.M., RyanD., EckertR.L.S100 protein subcellular localization during epidermal differentiation and psoriasis // J. Histochem. Cytochem.2003. V. 51 P. 675-85.
  24. MirmohammadsadeghA, TschakarjanE, LjoljicAet al.Calgranulin C is overexpressed in lesional psoriasis // J. Invest. Dermatol.2000 V. 114. P.1207-8.
  25. Quekenborn-TrinquetV., FogelP., Aldana-JammayracO.et al.Gene expression profiles in psoriasis: analysis of impact of body site location and clinical severity //Br. J. Dermatol.2005. V. 152. P. 489-504.
  26. Kulski J., Kenworthy W., Bellgard M. et al. Gene expression profiling of Japanese psoriatic skin reveals an increased activity in molecular stress and immune response signals // J.Mol. Med. 2005. V. 85. P. 964-975.
  27. Yao Y., Richman L.,Morehouse C. et al.Type I Interferon: Potential Therapeutic Target for Psoriasis - // PLoS One. 2008. V.3. № 7. e2737. P.1-14.
  28. Sonkoly E., Wei T., Janson P. et al.  MicroRNAs: novel regulators involved in the pathogenesis of Psoriasis - // PLoS ONE 2007. V.2. №7. P. 610.
  29. Livak K., Schmittgen T.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method // Methods. 2001. V. 25. № 4. P. 402-8.
  30. Adrian R. Photochemotherapy in psoriasis and other skin diseases // Am. Fam. Physician. 1981. V. 23. №5. P. 95-100.
  31. Roth J., Sunderkotter C., Goebeler M.,et al. Expression of the calcium-binding proteins MRP8 and MRP14 by early infiltrating cells in experimental contact dermatitis // Int. Arch. Allergy Immunol.1992 V.98(2) P.140-145.
  32. Frosch M., Strey A., Vogl T. et al.Mye­loid-related proteins 8 and 14 are specifically secreted during interac­tion of phagocytes and activated en­dothelium and are useful markers for monitoring disease activity in pauciarticular­onset juvenile rheumatoid arthritis // Arthritis Rheum. 2000 V.43(3) P.628-637.
  33. Wilkinson M.M., Busuttil A., Hayward C. et al. Expression pattern of two related cystic fibrosis-associated calcium-binding proteins in normal and abnormal tissues // J. Cell. Sci. 1988. V. 91(pt 2). P. 221-230.